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From 1976 to 2004, we followed 71751 participants of the Nurses’ Health Study and identified 676 invasive endometrial cancer
cases. Birthweight, assessed in 1992, was not associated with the incidence of endometrial cancer. No effect modification by
menopausal status was observed, but statistical power to detect an interaction was limited.
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Endometrial cancer is the commonest invasive gynecologic cancer
in women in the United States, with nearly 40000 new cases
diagnosed each year (American Cancer Society, 2007). Birthweight
and intrauterine exposures have been related to the risk of breast
cancer (Michels and Xue, 2006), childhood leukaemia (McLaughlin
et al, 2006) and testicular cancer (Michos et al, 2007). However,
data are limited regarding the potential influence of early life
exposures on endometrial cancer risk. Potential mechanisms for
an association between high birthweight and increased breast
cancer risk include exposure to elevated maternal pregnancy
oestrogen levels (Petridou et al, 1990; Ekbom et al, 1992), and
insulin-like growth factor-I levels (Yang and Yu, 2000; Ostlund
et al, 2002), both of which also affect the development of
endometrial cancer (Ayabe et al, 1997; Adami et al, 2002). Prenatal
nutrition may regulate body size later in life by altering the
number of adipocytes (Sayer and Cooper, 2005), reprogram
metabolism or influence leptin resistance (Phillips et al, 1999;
Breier et al, 2001). As obesity is an established risk factor of
endometrial cancer for premenopausal and postmenopausal
women (Adami et al, 2002), birthweight as a marker of prenatal
nutrition may plausibly influence its development.
Using data from 28 years of follow-up of 71751 women
participating in the Nurses’ Health Study (NHS), we examined
the association between birthweight and incidence of endometrial
cancer later in life.
MATERIAL AND METHODS
The NHS was established in 1976, when 121700 married registered
nurses age 30–55 years replied to a baseline questionnaire and
received questionnaires biennially by mail to update information
on demographic, anthropometric, and life style factors, and on
newly diagnosed disease. For the current analysis, we excluded
women with missing birthweight data, prevalent cases of
endometrial or other cancers, and women with hysterectomy at
baseline. During follow-up, women were censored if they reported
recently diagnosed in situ or invasive endometrial cancer, had a
hysterectomy, died or were lost to follow-up.
In 1992, we asked participants to report their own birthweight
with the following options: o2.500, 2500–o3182, 3182–o3863,
3863–o4545, X4545g. On each biennial questionnaire, partici-
pants were asked whether they had been newly diagnosed with
endometrial cancer during the previous 2 years. The National
Death Index was also routinely searched for deaths among women
who did not respond to the questionnaires. For endometrial
cancers reported by women or their next of kin for those who had
died, permission was requested to review the relevant medical
records. Study physicians reviewed all medical records and
pathological reports to confirm their diagnosis. Cases included
in this study were invasive epithelial endometrial cancers with
stage greater than IA in the FIGO staging system.
At baseline and during follow-up, we inquired about a variety
of personal characteristics including reproductive and life
style factors, many being risk factors for endometrial cancer.
Information on age, age at menarche, age at first birth and
height was obtained at baseline in 1976. Other early life
exposures including premature birth (2þ weeks premature)
and duration of having been breast-fed were assessed in 1992,
and birth order was queried in 2004. Weight at age 18 was
assessed in 1980. Somatotype at age 5 and 10 was assessed in
1988 by asking participants to choose from nine diagrams
that best depicted their figure outline at each age. Maternal
vital status and family history of endometrial cancer was asked
in 1996. Other covariates were inquired and updated during
follow-up.
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trial cancer was analysed using a Cox proportional hazards model.
Three covariate-adjusted models were pursued. In the first model
(model I), we adjusted only for family history of endometrial
cancer and other early life exposures including birth order,
duration of being breast-fed and premature birth, in addition to
age. In the second (model II), we also included other established or
potential risk factors for endometrial cancer. In the third (model
III), we additionally adjusted for anthropometric factors, including
somatotype at ages 5 and 10, BMI at age 18, and current
BMI. Though covariate-adjusted models II and III have better
goodness of fit due to additional adjustment for potential risk
factors of endometrial cancer, these factors are subsequent to
birthweight and could conceivably mediate the effect of birth-
weight on endometrial cancer risk. Therefore, adjusted model I
would be the preferred model to estimate the overall effect of
birthweight.
As birthweight was not assessed until 1992, we conducted a
sensitivity analysis restricting follow-up to 1992–2004 and
compared the results with the primary analysis using the entire
follow-up. We also evaluated potential effect modification by
menopausal status, anthropometric factors, and other early-life
exposures.
RESULTS
During 1678702 person-years of follow-up among 71751 women,
676 cases of incident endometrial cancer were confirmed. Based on
the eligible person-years, the follow-up rate for the entire cohort in
Table 2 Hazard ratio of endometrial cancer by birthweight among 71751 participants of the Nurses’ Health Study during follow-up from 1976–2004 and
from 1992–2004
HR (95% CI)
Birthweight (g) Person-years No. of cases Age-adjusted Covariate –adjusted I
a Covariate –adjusted II
b Covariate –adjusted III
c
Follow-up 1976–2004
X3863 221515 84 1.0 1.0 1.0 1.0
3182–o3863 750698 307 1.14 (0.89–1.46) 1.15 (0.90–1.47) 1.14 (0.89–1.47) 1.18 (0.92–1.51)
2500–o3182 521674 208 1.10 (0.85–1.42) 1.10 (0.84–1.42) 1.08 (0.83–1.41) 1.15 (0.88–1.50)
o2500 184815 77 1.14 (0.83–1.57) 1.12 (0.79–1.57) 1.09 (0.77–1.54) 1.13 (0.79–1.60)
P for trend 0.52 0.63 0.74 0.48
Follow-up 1992–2004
X3863 70871 54 1.0 1.0 1.0 1.0
3182–o3863 245954 207 1.16 (0.85–1.56) 1.16 (0.86–1.58) 1.16 (0.86–1.58) 1.19 (0.87–1.61)
2500–o3182 171030 123 0.99 (0.72–1.37) 1.00 (0.72–1.38) 0.98 (0.71–1.36) 1.03 (0.74–1.43)
o2500 60391 52 1.16 (0.79–1.71) 1.19 (0.79–1.81) 1.17 (0.77–1.78) 1.19 (0.78–1.82)
P for trend 0.91 0.87 0.96 0.79
aHazard ratio (HR) and 95% confidence interval (CI) were adjusted for age (continuous), premature birth (yes, no), birth order (first, second, third, fourth or above), duration of
being breast fed in infancy (no, p3, 4–8, X9 months), and family history of endometrial cancer (yes, no).
bHR and 95% CI were adjusted for age (continuous), premature
birth (yes, no), birth order (first, second, third, fourth or above), duration of being breast fed in infancy (no, p3, 4–8, X9 months), and family history of endometrial cancer (yes,
no), age at menarche (p10, 11, 12, 13, 14, 15+ years), current and past contraceptive use (never, pasto5 years, pastX5 years, currento 5years, currentX5 years), parity
(1,2,3,4+), age at first birth (p24, 25–30, 30+ years), age at last birth (p24, 25–29, 30–34, 35–40, 440 years), physical activity (o3, 3–8, 9–17, 18–26, 27–41, 42+ mets
per week), cigarette smoking (never, 1–20, 21–40, 41+ pack-years), tamoxifen use (never, past and o5 years, past and X5 years, current and o5 years, current and X5 years),
menopausal status (yes, no), age at menopause (o50, 50–52, 53+ years), and postmenopausal hormone use (never, past and o5 years, past and X5 years, current and o5
years, current and X5 years).
cHR and 95% CI were adjusted for age (continuous), premature birth (yes, no), birth order (first, second, third, fourth or above), duration of being
breast fed in infancy (no, p3, 4–8, X9 months), and family history of endometrial cancer (yes, no), age at menarche (p10, 11, 12, 13, 14, 15+ years), current and past
contraceptive use (never, pasto5 years, pastX5 years, currento5 years, currentX5 years), parity (1,2,3,4+), age at first birth (p24, 25–30, 30+ years), age at last birth (p24,
25–29, 30–34, 35–40, 440 years), physical activity (o3, 3–8, 9–17, 18–26, 27–41, 42+ mets per week), cigarette smoking (never, 1–20, 21–40, 41+ pack-years),
tamoxifen use (never, past and o5 years, past and X5 years, current and o5 years, current and X5 years), menopausal status (yes, no), age at menopause (o50, 50–52, 53+
years), postmenopausal hormone use (never, past and o5 years, past and X5 years, current and o5 years, current and X5 years), BMI (continuous in kgm
 2), BMI at age 18
(continuous in kgm
 2), and somatotype at age 5 and age at 10 (ranked from 1–9).
Table 1 Age-standardised distribution of demographic characteristics among 71751 women according to birthweight throughout follow-up 1976–2004
(N¼1678702 person-years)
Birthweight (g)
Demographic characteristics o2500 2500–o3182 3182–o3863 X3863
Family history of endometrial cancer (%) 3.4 2.9 3.0 3.7
Premature birth (%) 35.6 2.9 0.7 0.3
First born (%) 40.6 39.2 37.9 29.1
Breast fed (%) 42.4 52.0 57.0 62.3
Age at menarche (mean) (years) 12.4 12.4 12.4 12.5
BMI at age 18 (Mean) (kgm
 2) 21.1 21.0 21.5 21.9
Height (Mean) (cm) 162 163 165 166
Nulliparous (%) 7.0 6.9 6.4 7.5
Mean number of children among parous women 3.2 3.2 3.2 3.2
Premenopausal (%) 35.3 35.9 36.2 35.7
Ever smoked (%) 54.3 54.8 56.1 58.9
Current BMI (Mean) (kgm
 2) 25.3 25.0 25.5 25.8
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birthweight were less likely to have been prematurely delivered
and to be the first born of their mother, were more likely breastfed,
more likely to have ever smoked, and were slightly taller, than
women with lower birthweight (Table 1).
Birthweight was not associated with endometrial cancer (HR
(95% CI)¼1.14 (0.83–1.57), 1.10 (0.85–1.42), 1.14 (0.89, 1.46) for
a birthweight of o2500, 2500–o3182, 3182–o3863g, respec-
tively, as compared to X3863g, P for trend¼0.52) in the age-
adjusted analysis (Table 2). Results did not differ substantially
after adjusting for other potential confounders (covariate-adjusted
models I–III) (Table 2). When restricting the analysis to follow-up
from 1992 to 2004, the effect estimates did not change substantially
from the primary analysis (Table 2). A test for interaction also did
not suggest significant heterogeneity with regard to period of
follow-up (1976–1992 vs 1992–2004) (P¼0.80).
The association between birthweight and endometrial cancer did
not vary significantly by menopausal status (P¼0.41); however,
statistical power was limited for premenopausal cases (Table 3). It
also did not vary by somatotype at age five, somatotype at age 10,
BMI at age 18, or current BMI (all P for interactionX0.32).
DISCUSSION
In two previous prospective cohort studies, both from Sweden, the
risk of endometrial cancer has been investigated in relation to
birthweight. Based on 112 cases, the incidence of endometrial
cancer in women with birthweight of X4000g was found to be
almost half that of women with birthweight of o3000g (HR¼0.55
(95% CI 0.36–1.17)) (McCormack et al, 2005). Based on 73, no
significant association was found between birthweight and
endometrial cancer (HR¼0.65 (95% CI 0.34–1.24) comparing
the incidence in women with birthweight o2500g to that in
women 43000g) (Lof et al, 2007). With more than triple the cases
of all previous studies combined, results from the current study do
not suggest an association.
Endometrial cancer involves cancerous growth of the endome-
trium. Unlike breast epithelium, in which terminal differentiation
occurs largely during the first full-term pregnancy, the endometrial
lining undergoes repeated division and differentiation throughout
the reproductive life of a woman. Though birthweight has been
related to a higher intrauterine exposure to oestrogen (Petridou
et al, 1990) and IGF-I (Yang and Yu, 2000), the relation of
birthweight to the profile of endogenous hormone later in life is
less clear. In one study, birthweight was not associated with overall
premenopausal sex hormone levels, but was inversely associated
with luteal estrone and estrone sulphate (Tworoger et al, 2006).
Similarly, birthweight was found to be only weakly associated with
serum IGF-I levels in adulthood (Schernhammer et al, 2007).
The statistical power of this study would allow us to detect a
modest association, if it exists. Many risk factors for endometrial
cancer and other early life exposures were assessed and accounted
for in the analysis. Though birthweight was queried 16 years after
the start of follow-up, when compared with the analysis restricted
to prospective follow-up, results including the entire follow-up of
28 years did not differ appreciably. We have previously compared
self-reported birthweight with data derived from birth certificates
and found self-reported birthweight to be highly reliable (r¼0.74)
(Troy et al, 1996).
Current research suggests that women can decrease their risk of
endometrial cancer mainly through maintaining normal weight,
modifying lifestyle, and optimal use of oral contraceptives and
postmenopausal hormones (Adami et al, 2002). However, a large
number of new cases of endometrial cancer, especially among
younger women cannot be accounted for by known risk factors.
Clarification of any association between early life exposures and
endometrial cancer risk awaits further investigation.
Table 3 Hazard ratio of endometrial cancer by birthweight among 71751 participants of the Nurses’ Health Study during follow-up from 1976–2004
stratified by menopausal status
HR (95% CI)
Birthweight (g) Person-years No. of cases Age-adjusted Covariate –adjusted I
a Covariate –adjusted II
b Covariate –adjusted III
c
Premenopausal
X3863 72535 14 1.0 1.0 1.0 1.0
3182–o3863 280538 43 0.77 (0.41–1.44) 0.79 (0.42–1.48) 0.90 (0.46–1.78) 0.95 (0.47–1.91)
2500–o3182 194984 31 0.85 (0.44–1.63) 0.79 (0.41–1.54) 0.87 (0.43–1.76) 0.95 (0.46–1.97)
o2500 67533 8 0.59 (0.24–1.42) 0.45 (0.17–1.19) 0.40 (0.14–1.15) 0.43 (0.14–1.28)
P for trend 0.37 0.18 0.17 0.27
Postmenopausal
X3863 130992 70 1.0 1.0 1.0 1.0
3182–o3863 409653 264 1.21 (0.93–1.58) 1.21 (0.93–1.58) 1.20 (0.92–1.57) 1.23 (0.94–1.61)
2500–o3182 284140 170 1.12 (0.85–1.48) 1.12 (0.85–1.49) 1.10 (0.83–1.46) 1.17 (0.87–1.56)
o2500 102233 67 1.21 (0.86–1.69) 1.21 (0.84–1.74) 1.19 (0.82–1.72) 1.22 (0.84–1.77)
P for trend 0.46 0.48 0.58 0.38
aHazard ratio (HR) and 95% confidence interval (CI) were adjusted for age (continuous), premature birth (yes, no), birth order (first, second, third, fourth or above), duration of
being breast fed in infancy (no, p3, 4–8, X9 months), and family history of endometrial cancer (yes, no).
bHR and 95% CI were adjusted for age (continuous), premature
birth (yes, no), birth order (first, second, third, fourth or above), duration of being breast fed in infancy (no, p3, 4–8, X9 months), and family history of endometrial cancer (yes,
no), age at menarche (p10, 11, 12, 13, 14, 15+ years), current and past contraceptive use (never, pasto5 years, pastX5 years, currento 5years, currentX5 years), parity
(1,2,3,4+), age at first birth (p24, 25–30, 30+ years), age at last birth (p24, 25–29, 30–34, 35–40, 440 years), physical activity (o3, 3–8, 9–17, 18–26, 27–41, 42+ mets
per week), cigarette smoking (never, 1–20, 21–40, 41+ pack–years), tamoxifen use (never, past and o5 years, past and X5 years, current and o5 years, current and
X5 years). Age at menopause (o50, 50–52, 53+ years), and postmenopausal hormone use (never, past and o5 years, past and X5 years, current and o5 years, current and
X5 years) were additionally adjusted for in the analysis of postmenopausal endometrial cancer.
cHR and 95% CI were adjusted for age (continuous), premature birth (yes, no),
birth order (first, second, third, fourth or above), duration of being breast fed in infancy (no, p3, 4–8, X9 months), and family history of endometrial cancer (yes, no), age at
menarche (p10, 11, 12, 13, 14, 15+ years), current and past contraceptive use (never, pasto5years, pastX5years, currento5 years, currentX5 years), parity (1,2,3,4+), age at
first birth (p24, 25–30, 30+ years), age at last birth (p24, 25–29, 30–34, 35–40, 440 years), physical activity (o3, 3–8, 9–17, 18–26, 27–41, 42+ mets per week),
cigarette smoking (never, 1–20, 21–40, 41+ pack-years), tamoxifen use (never, past and o5 years, past and X5 years, current and o5 years, current and X5 years), BMI
(continuous in kgm
 2), BMI at age 18 (continuous in kgm
 2), and somatotype at age 5 and age at 10 (ranked from 1–9). Age at menopause (o50, 50–52, 53+ years), and
postmenopausal hormone use (never, past and o5 years, past and X5 years, current and o5 years, current and X5 years) were additionally adjusted for in the analysis of
postmenopausal endometrial cancer.
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